Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells.

Abstract

PURPOSE Recent studies of Hodgkin's lymphoma (HL) have suggested that the presence of regulatory T cells in the reactive background may explain the inhibition of the antitumoral host immune response observed in these patients. This study aimed to assess the relevance of regulatory T cells and CTLs present in the background of HL samples in the prognosis of a series of classic HL (cHL) patients. EXPERIMENTAL DESIGN Expression of granzyme B and TIA-1 (markers for CTL) and FOXP3 (a marker for regulatory T cells) were evaluated independently by immunohistochemistry in tissue microarrays of 257 cHL patients and correlated with patient outcome. RESULTS The combined influence of the presence of FOXP3(+) and TIA-1(+) cells distinguished three risk groups of patients with 5-year overall survival of 100%, 88%, and 73%. The presence of a small number of FOXP3(+) cells and a high proportion of TIA-1(+) cells in the infiltrate represent an independent prognostic factor that negatively influenced event-free survival and disease-free survival in cHL. Compared with the features at diagnosis, relapsed samples tended to have more TIA-1(+) cells and a lower proportion of FOXP3(+) cells in the reactive background. CONCLUSIONS These data suggest that low infiltration of FOXP3(+) cells in conjunction with high infiltration of TIA-1(+) cells in cHL may represent biological markers predicting an unfavorable outcome. Moreover, the variation of these markers over the course of the disease implies a possible role for them in the progression of HL cases.

3 Figures and Tables

05001000'05'06'07'08'09'10'11'12'13'14'15'16'17
Citations per Year

5,618 Citations

Semantic Scholar estimates that this publication has 5,618 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Alvaro2005OutcomeIH, title={Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells.}, author={Tom{\'a}s Alvaro and Maryl{\`e}ne Lejeune and Ma Teresa Salvad{\'o} and Ram{\'o}n Bosch and Juan F Garc{\'i}a and Joaqu{\'i}n Ja{\'e}n and Alison H Banham and Giovanna Roncador and Carlos Montalb{\'a}n and Miguel A Piris}, journal={Clinical cancer research : an official journal of the American Association for Cancer Research}, year={2005}, volume={11 4}, pages={1467-73} }